突变TP53急性髓系白血病和高危骨髓增生异常综合征的分子特征
对2200例AML/MDS-EB标本行下一代测序,230例(10.5%)检出TP53突变,中位变异等位基因频率47%。TP53突变型AML与MDS-EB在分子特征和生存上无显著差异,2年总生存率12.8%,各分子特征均与生存无显著关联。
要点
- TP53突变见于10.5%(230/2200)的AML/MDS-EB,双等位突变占76%(174/230)。
- TP53突变型AML与MDS-EB的分子特征及生存均无显著差异,2年总生存率12.8%。
- TP53突变各分子特征(等位状态、突变数目、克隆大小、共存突变)均与生存无显著关联。
核心结论
- TP53突变型AML与MDS-EB在分子特征和生存上无差异,应视为一种独特的分子疾病实体。
研究设计与样本
- 对2200例AML/MDS-EB标本行下一代测序,评估TP53突变等位状态、突变数目、克隆大小、共存突变、细胞遗传学和分子微小残留病,并分析其与总生存的关联。
主要发现
- 230例(10.5%)检出TP53突变,中位变异等位基因频率47%;双等位突变174例(76%),多个TP53突变49例(21%),共存突变113例(49%)。
- TP53突变型AML与MDS-EB在上述分子特征上均无显著差异。
- TP53突变患者预后差,2年总生存率12.8%;AML与MDS-EB之间无生存差异。
- 各分子特征均与TP53突变型AML/MDS-EB的生存无显著关联。
- 多数患者完全缓解时深度测序仍可检出TP53突变(73%),残留突变TP53检测与生存无关联。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of prognostic impact for individual patients. We performed in-depth clinical and molecular analysis of mutant TP53 AML and MDS-EB to dissect the molecular characteristics in detail and determine its impact on survival. We performed next-generation sequencing on 2200 AML/MDS-EB specimens and assessed the TP53 mutant allelic status (mono- or bi-allelic), the number of TP53 mutations, mutant TP53 clone size, concurrent mutations, cytogenetics, and mutant TP53 molecular minimal residual disease and studied the associations of these characteristics with overall survival. TP53 mutations were detected in 230 (10.5%) patients with AML/MDS-EB with a median variant allele frequency of 47%. Bi-allelic mutant TP53 status was observed in 174 (76%) patients. Multiple TP53 mutations were found in 49 (21%) patients. Concurrent mutations were detected in 113 (49%) patients. No significant difference in any of the aforementioned molecular characteristics of mutant TP53 was detected between AML and MDS-EB. Patients with mutant TP53 have a poor outcome (2-year overall survival, 12.8%); however, no survival difference between AML and MDS-EB was observed. Importantly, none of the molecular characteristics were significantly associated with survival in mutant TP53 AML/MDS-EB. In most patients, TP53 mutations remained detectable in complete remission by deep sequencing (73%). Detection of residual mutant TP53 was not associated with survival. Mutant TP53 AML and MDS-EB do not differ with respect to molecular characteristics and survival. Therefore, mutant TP53 AML/MDS-EB should be considered a distinct molecular disease entity.
引用
- Grob T, Al Hinai ASA, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022. PMID: 35108372. doi:10.1182/blood.2021014472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。